THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE

The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SERNO, Peter, WATTERS, Siobhan, WENGNER, Antje Margret, KRICKAU, Dennis, BAIRLEIN, Michaela, LAGKADINOU, Eleni, ASSI, Pardis, KRAUSE, Michael, WILKINSON, Gary
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	SERNO, Peter WATTERS, Siobhan WENGNER, Antje Margret KRICKAU, Dennis BAIRLEIN, Michaela LAGKADINOU, Eleni ASSI, Pardis KRAUSE, Michael WILKINSON, Gary
description	The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2022117973A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2022117973A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2022117973A13</originalsourceid><addsrcrecordid>eNrjZIgN8XBVcAwJUvD29HMMdlXw9PPwdPIM8Q9ScHKMNLSwNDU2MVFwA3JDwZIKIOUhQa6OIb6ufiEK_m4KjgoekQGuQboBQf4-nm6uQY4hnmGuCi6ewa5A43gYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXxosJGBkZGhobmlubGjoTFxqgAvkDK6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE</title><source>esp@cenet</source><creator>SERNO, Peter ; WATTERS, Siobhan ; WENGNER, Antje Margret ; KRICKAU, Dennis ; BAIRLEIN, Michaela ; LAGKADINOU, Eleni ; ASSI, Pardis ; KRAUSE, Michael ; WILKINSON, Gary</creator><creatorcontrib>SERNO, Peter ; WATTERS, Siobhan ; WENGNER, Antje Margret ; KRICKAU, Dennis ; BAIRLEIN, Michaela ; LAGKADINOU, Eleni ; ASSI, Pardis ; KRAUSE, Michael ; WILKINSON, Gary</creatorcontrib><description>The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220421&DB=EPODOC&CC=US&NR=2022117973A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220421&DB=EPODOC&CC=US&NR=2022117973A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SERNO, Peter</creatorcontrib><creatorcontrib>WATTERS, Siobhan</creatorcontrib><creatorcontrib>WENGNER, Antje Margret</creatorcontrib><creatorcontrib>KRICKAU, Dennis</creatorcontrib><creatorcontrib>BAIRLEIN, Michaela</creatorcontrib><creatorcontrib>LAGKADINOU, Eleni</creatorcontrib><creatorcontrib>ASSI, Pardis</creatorcontrib><creatorcontrib>KRAUSE, Michael</creatorcontrib><creatorcontrib>WILKINSON, Gary</creatorcontrib><title>THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE</title><description>The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZIgN8XBVcAwJUvD29HMMdlXw9PPwdPIM8Q9ScHKMNLSwNDU2MVFwA3JDwZIKIOUhQa6OIb6ufiEK_m4KjgoekQGuQboBQf4-nm6uQY4hnmGuCi6ewa5A43gYWNMSc4pTeaE0N4Oym2uIs4duakF-fGpxQWJyal5qSXxosJGBkZGhobmlubGjoTFxqgAvkDK6</recordid><startdate>20220421</startdate><enddate>20220421</enddate><creator>SERNO, Peter</creator><creator>WATTERS, Siobhan</creator><creator>WENGNER, Antje Margret</creator><creator>KRICKAU, Dennis</creator><creator>BAIRLEIN, Michaela</creator><creator>LAGKADINOU, Eleni</creator><creator>ASSI, Pardis</creator><creator>KRAUSE, Michael</creator><creator>WILKINSON, Gary</creator><scope>EVB</scope></search><sort><creationdate>20220421</creationdate><title>THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE</title><author>SERNO, Peter ; WATTERS, Siobhan ; WENGNER, Antje Margret ; KRICKAU, Dennis ; BAIRLEIN, Michaela ; LAGKADINOU, Eleni ; ASSI, Pardis ; KRAUSE, Michael ; WILKINSON, Gary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2022117973A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SERNO, Peter</creatorcontrib><creatorcontrib>WATTERS, Siobhan</creatorcontrib><creatorcontrib>WENGNER, Antje Margret</creatorcontrib><creatorcontrib>KRICKAU, Dennis</creatorcontrib><creatorcontrib>BAIRLEIN, Michaela</creatorcontrib><creatorcontrib>LAGKADINOU, Eleni</creatorcontrib><creatorcontrib>ASSI, Pardis</creatorcontrib><creatorcontrib>KRAUSE, Michael</creatorcontrib><creatorcontrib>WILKINSON, Gary</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SERNO, Peter</au><au>WATTERS, Siobhan</au><au>WENGNER, Antje Margret</au><au>KRICKAU, Dennis</au><au>BAIRLEIN, Michaela</au><au>LAGKADINOU, Eleni</au><au>ASSI, Pardis</au><au>KRAUSE, Michael</au><au>WILKINSON, Gary</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE</title><date>2022-04-21</date><risdate>2022</risdate><abstract>The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper-proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US2022117973A1
source	esp@cenet
subjects	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SERNO,%20Peter&rft.date=2022-04-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2022117973A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true